Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for advanced ovarian cancer (for relapsed disease only) (Review TA91 & TA222) (ID468)

Source:
Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA
Publisher:
Centre for Reviews and Dissemination
Publication date:
03 January 2014

Abstract

Bibliographic details

 Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for advanced ovarian cancer (for relapsed disease only) (Review TA91 & TA222) (ID468). Health Technology Assessment

Status

This is a bibliographic record of an ongoing health technology assessment being undertaken by a member of INAHTA. Links to the published report and any other relevant documentation will be added when available.

Indexing status

Subject indexing assigned by CRD

Index terms

Antibiotics, Antineoplastic; Doxorubicin; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan